Education
About Us
Working with TipRanks
Follow Us
Avidity Biosciences Inc (RNA)
NASDAQ:RNA
RNA Analyst Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
RNA Stock 12 Month Forecast
Average Price Target
$67.83
▲(103.69% Upside)
| Highest Price Target$96.00 | Average Price Target$67.83 | Lowest Price Target$48.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
Reiterated
03/18/25
Scotiabank
Reiterated
03/18/25
Leerink Partners
Reiterated
03/17/25
Citi
Reiterated
03/17/25
H.C. Wainwright
Reiterated
03/17/25
Needham
Reiterated
03/17/25
Bank of America Securities
Reiterated
03/17/25
BMO Capital
Reiterated
03/17/25
Barclays
Reiterated
02/28/25
Cantor Fitzgerald
Reiterated
02/28/25
Wells Fargo
$75→$70
Buy
110.21%
Upside
Reiterated
02/28/25
Avidity Biosciences (RNA) Gets a Buy from Wells Fargo
RBC Capital
$67→$61
Buy
83.18%
Upside
Reiterated
02/28/25
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Ligand Pharma (NASDAQ: LGND) and Avidity Biosciences (NASDAQ: RNA)
Chardan Capital
$65
Buy
95.20%
Upside
Reiterated
11/13/24
Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology
Goldman Sachs
$59
Buy
77.18%
Upside
Reiterated
10/30/24
Goldman Sachs reiterates Buy Rating on Avidity Biosciences (RNA)Goldman Sachs analyst Corinne Johnson reiterated a Buy rating and $59.00 price target on Avidity Biosciences (NASDAQ: RNA).
Evercore ISI
$54→$53
Buy
59.16%
Upside
Reiterated
08/26/24
Avidity Biosciences price target lowered to $53 from $54 at Evercore ISIAvidity Biosciences price target lowered to $53 from $54 at Evercore ISI
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Reiterated
03/18/25
Scotiabank
Reiterated
03/18/25
Leerink Partners
Reiterated
03/17/25
Citi
Reiterated
03/17/25
H.C. Wainwright
Reiterated
03/17/25
Needham
Reiterated
03/17/25
Bank of America Securities
Reiterated
03/17/25
BMO Capital
Reiterated
03/17/25
Barclays
Reiterated
02/28/25
Cantor Fitzgerald
Reiterated
02/28/25
Wells Fargo
$75→$70
Buy
110.21%
Upside
Reiterated
02/28/25
Avidity Biosciences (RNA) Gets a Buy from Wells Fargo
RBC Capital
$67→$61
Buy
83.18%
Upside
Reiterated
02/28/25
Analysts Offer Insights on Healthcare Companies: Viridian Therapeutics (NASDAQ: VRDN), Ligand Pharma (NASDAQ: LGND) and Avidity Biosciences (NASDAQ: RNA)
Chardan Capital
$65
Buy
95.20%
Upside
Reiterated
11/13/24
Promising Outlook for Avidity Biosciences: Strategic Focus on Genetic Targeting and Innovative AOC Technology
Goldman Sachs
$59
Buy
77.18%
Upside
Reiterated
10/30/24
Goldman Sachs reiterates Buy Rating on Avidity Biosciences (RNA)Goldman Sachs analyst Corinne Johnson reiterated a Buy rating and $59.00 price target on Avidity Biosciences (NASDAQ: RNA).
Evercore ISI
$54→$53
Buy
59.16%
Upside
Reiterated
08/26/24
Avidity Biosciences price target lowered to $53 from $54 at Evercore ISIAvidity Biosciences price target lowered to $53 from $54 at Evercore ISI
RNA Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
7
7
9
17
27
Buy
18
17
12
1
2
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
25
24
21
18
29
Each month's total comprises the sum of three months' worth of ratings.
RNA Financial Forecast
RNA Stock Forecast FAQ
What is RNA’s average 12-month price target, according to analysts?
Based on analyst ratings, Avidity Biosciences Inc’s 12-month average price target is $67.83.
What is RNA’s upside potential, based on the analysts’ average price target?
Avidity Biosciences Inc has 103.69% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is RNA a Buy, Sell or Hold?
Avidity Biosciences Inc has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
What is Avidity Biosciences Inc’s price target?
The average price target for Avidity Biosciences Inc is $67.83. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $96.00 ,the lowest forecast is $48.00. The average price target represents 103.69% Increase from the current price of $33.3.
The highest analyst price target is $96.00 ,the lowest forecast is $48.00. The average price target represents 103.69% Increase from the current price of $33.3.
What do analysts say about Avidity Biosciences Inc?
Avidity Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
How can I buy shares of RNA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.